Search CTL/CD8+ T-Cell Epitope Database

Found 4 matching records:

Displaying record number 58850

HXB2 Location	Pol(334-344) RT(179-189) DNA(3084..3116)	Pol Epitope Map
Author Location	RT
Epitope	`VIYQYMDDLYV`	Epitope Alignment
		Show epitope variants
Epitope Name	VV11
Subtype	B
Species (MHC/HLA)	human(A*0201)
Immunogen	HIV-1 infection
Country	Germany
Experimental methods	CD8 T-cell Elispot - IFNγ, Intracellular cytokine staining, Other
Keywords	HAART, ART, escape, optimal epitope, drug resistance

Notes

CTL control of a drug resistance-containing mutant HIV-1 was detected. The lamivudine/emtricitabine-generated M184V escape found within epitopes YQYMDDLYV or VIYQYMDDLYV was able to be recognized, resulting in lower viral load (VL) in vivo and ability to inhibit viral replication in vitro. Since CTL responses were detected against RT in ART-failing subjects, complete suppression of VL in the presence of drug-resistant HIV-1 without changing ART is possible.
Novel epitope ,VIYQYMDDLYV (VV11), was fine-mapped as being optimal, and confirmed to be restricted by A*0201. VV11 was recognized best by a treatment-naive subject who could also mount a response with high avidity against the mutant, VIYQYvDDLYV.

References

Vollbrecht2012 Thomas Vollbrecht, Josef Eberle, Julia Roider, Silja Bühler, Renate Stirner, Nadja Henrich, Ulrich Seybold, Johannes R. Bogner, and Rika Draenert. Control of M184V HIV-1 Mutants by CD8 T-Cell Responses. Med. Microbiol. Immunol., 201(2):201-211, May 2012. PubMed ID: 22200907. Show all entries for this paper.

Displaying record number 58870

HXB2 Location	Pol(334-344) RT(179-189) DNA(3084..3116)	Pol Epitope Map
Author Location	RT
Epitope	`VIYQYVDDLYV`	Epitope Alignment
Epitope Name	VV11
Subtype	B
Species (MHC/HLA)	human(A*0201)
Immunogen	HIV-1 infection
Country	Germany
Experimental methods	CD8 T-cell Elispot - IFNγ, Intracellular cytokine staining, Other
Keywords	HAART, ART, escape, optimal epitope, drug resistance

Notes

CTL control of a drug resistance-containing mutant HIV-1 was detected. The lamivudine/emtricitabine-generated M184V escape found within epitopes YQYMDDLYV or VIYQYMDDLYV was able to be recognized, resulting in lower viral load (VL) in vivo and ability to inhibit viral replication in vitro. Since CTL responses were detected against RT in ART-failing subjects, complete suppression of VL in the presence of drug-resistant HIV-1 without changing ART is possible.
Epitope VIYQYVDDLYV was discovered as a variant of wt epitope VIYQYmDDLYV, but was able to elicit response from a treatment-naive subject with high avidity. In all emtricitabine-lamivudine users who carried M184V-virus, however, VIYQYVDDLYV is the optimal epitope to elicit much stronger CTL response.

References

Displaying record number 58847

HXB2 Location	Pol(336-344) RT(181-189) DNA(3090..3116)	Pol Epitope Map
Author Location	RT
Epitope	`YQYMDDLYV`	Epitope Alignment
		Show epitope variants
Epitope Name	YV9
Subtype	B
Species (MHC/HLA)	human(A*0201)
Immunogen	HIV-1 infection
Country	Germany
Experimental methods	CD8 T-cell Elispot - IFNγ, Intracellular cytokine staining, Other
Keywords	HAART, ART, escape, optimal epitope, drug resistance

Notes

CTL control of a drug resistance-containing mutant HIV-1 was detected. The lamivudine/emtricitabine-generated M184V escape found within epitopes YQYVDDLYV or VIYQYVDDLYV was therefore able to be recognized, resulting in lower viral load (VL) in vivo and ability to inhibit viral replication in vitro. Since CTL responses were detected against RT in ART-failing subjects, complete suppression of VL in the presence of drug-resistant HIV-1 without changing ART is possible.
A previously putative epitope ,YQYMDDLYV (YV9), was fine-mapped as optimal and confirmed to be restricted by A*0201. YV9 was recognized best by treatment-naive subjects who could also mount a response with high avidity against the mutant, YQYvDDLYV. 2 subjects with response to YV9 were not HLA-A*0201-positive, but the cross-reacting HLA has not been found yet.

References

Displaying record number 58869

HXB2 Location	Pol(336-344) RT(181-189) DNA(3090..3116)	Pol Epitope Map
Author Location	RT
Epitope	`YQYVDDLYV`	Epitope Alignment
Subtype	B
Species (MHC/HLA)	human(A*0201)
Immunogen	HIV-1 infection
Country	Germany
Experimental methods	CD8 T-cell Elispot - IFNγ, Intracellular cytokine staining, Other
Keywords	HAART, ART, escape, optimal epitope, drug resistance

Notes

CTL control of a drug resistance-containing mutant HIV-1 was detected. The lamivudine/emtricitabine-generated M184V escape found within epitopes YQYVDDLYV or VIYQYVDDLYV was therefore able to be recognized, resulting in lower viral load (VL) in vivo and ability to inhibit viral replication in vitro. Since CTL responses were detected against RT in ART-failing subjects, complete suppression of VL in the presence of drug-resistant HIV-1 without changing ART is possible.
Epitope YQYVDDLYV was discovered as a variant of wt epitope YQYmDDLYV, but was able to elicit response from treatment-naive subjects with high avidity. In all emtricitabine-lamivudine users who carried M184V-virus, however, YQYVDDLYV is the optimal epitope to elicit much stronger CTL response.